Santen Pharmaceutical Co., Ltd.
SNPHY · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $549,644 | $569,577 | $485,875 | $548,833 |
| - Cash | $63,560 | $84,578 | $92,997 | $77,851 |
| + Debt | $241 | $0 | $34,229 | $0 |
| Enterprise Value | $486,326 | $484,999 | $427,107 | $470,982 |
| Revenue | $469 | $68,737 | $77,231 | $76,369 |
| % Growth | -99.3% | -11% | 1.1% | – |
| Gross Profit | $256 | $37,118 | $46,096 | $42,234 |
| % Margin | 54.7% | 54% | 59.7% | 55.3% |
| EBITDA | $104 | $12,070 | $18,485 | $15,830 |
| % Margin | 22.1% | 17.6% | 23.9% | 20.7% |
| Net Income | $55 | $5,878 | $8,791 | $8,693 |
| % Margin | 11.7% | 8.6% | 11.4% | 11.4% |
| EPS Diluted | 0.16 | 17.28 | 25.69 | 25.22 |
| % Growth | -99.1% | -32.7% | 1.9% | – |
| Operating Cash Flow | $40 | $53 | $18,890 | $13,730 |
| Capital Expenditures | -$11 | -$13 | -$927 | -$3,056 |
| Free Cash Flow | $30 | $41 | $17,963 | $10,674 |